INSERM, U897, ISPED, Université Bordeaux Segalen, Bordeaux, France.
Int J Epidemiol. 2012 Apr;41(2):433-45. doi: 10.1093/ije/dyr164. Epub 2011 Nov 28.
Using data from a large European collaborative study, we aimed to identify the circumstances in which treated HIV-infected individuals will experience similar mortality rates to those of the general population.
Adults were eligible if they initiated combination anti-retroviral treatment (cART) between 1998 and 2008 and had one prior CD4 measurement within 6 months. Standardized mortality ratios (SMRs) and excess mortality rates compared with the general population were estimated using Poisson regression. Periods of follow-up were classified according to the current CD4 count.
Of the 80 642 individuals, 70% were men, 16% were injecting drug users (IDUs), the median age was 37 years, median CD4 count 225/mm(3) at cART initiation and median follow-up was 3.5 years. The overall mortality rate was 1.2/100 person-years (PY) (men: 1.3, women: 0.9), 4.2 times as high as that in the general population (SMR for men: 3.8, for women: 7.4). Among 35 316 individuals with a CD4 count ≥500/mm(3), the mortality rate was 0.37/100 PY (SMR 1.5); mortality rates were similar to those of the general population in non-IDU men [SMR 0.9, 95% confidence interval (95% CI) 0.7-1.3] and, after 3 years, in women (SMR 1.1, 95% CI 0.7-1.7). Mortality rates in IDUs remained elevated, though a trend to decrease with longer durations with high CD4 count was seen. A prior AIDS diagnosis was associated with higher mortality.
Mortality patterns in most non-IDU HIV-infected individuals with high CD4 counts on cART are similar to those in the general population. The persistent role of a prior AIDS diagnosis underlines the importance of early diagnosis of HIV infection.
本研究利用来自大型欧洲合作研究的数据,旨在确定接受治疗的 HIV 感染者在何种情况下其死亡率与普通人群相似。
若患者于 1998 年至 2008 年间接受联合抗逆转录病毒治疗(cART),且在 cART 启动前 6 个月内有过一次 CD4 检测,则有资格入组。采用泊松回归法估计标准化死亡率(SMR)和与普通人群相比的超额死亡率。根据当前 CD4 计数将随访期分类。
在 80642 名患者中,70%为男性,16%为注射吸毒者(IDU),中位年龄为 37 岁,cART 启动时的中位 CD4 计数为 225/mm3,中位随访时间为 3.5 年。总死亡率为 1.2/100 人年(PY)(男性:1.3,女性:0.9),是普通人群的 4.2 倍(男性 SMR:3.8,女性 SMR:7.4)。在 35316 名 CD4 计数≥500/mm3 的患者中,死亡率为 0.37/100 PY(SMR 1.5);非 IDU 男性死亡率与普通人群相似[SMR 0.9,95%置信区间(95%CI)0.7-1.3],女性在 3 年后也相似(SMR 1.1,95%CI 0.7-1.7)。IDU 的死亡率仍然较高,但随着 CD4 计数较高的持续时间延长,死亡率呈下降趋势。既往 AIDS 诊断与死亡率升高相关。
大多数 CD4 计数较高的接受 cART 的非 IDU HIV 感染者的死亡模式与普通人群相似。既往 AIDS 诊断的持续作用突显了早期诊断 HIV 感染的重要性。